Tags

Type your tag names separated by a space and hit enter

A systematic review of invasive pneumococcal disease vaccine failures and breakthrough with higher-valency pneumococcal conjugate vaccines in children.
Expert Rev Vaccines. 2022 Feb; 21(2):201-214.ER

Abstract

INTRODUCTION

The pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccine (PHiD-CV/PCV10) and 13-valent pneumococcal conjugate vaccine (PCV13) protect against vaccine-serotype invasive pneumococcal disease (VT IPD). However, VT IPD can still occur in fully or partially vaccinated children (vaccine failure or breakthrough). We performed a systematic review of vaccine failures and breakthrough IPD with PCV10 and PCV13 in ≤5-year-olds.

AREAS COVERED

We searched Scopus/Medline/EMBASE to retrieve articles/abstracts published between 1/2008-7/2019. We excluded reports only including data from ≥6-year-olds, exclusively assessing PCV7-vaccinated children or children with comorbidities. Twenty-six reports (20 PCV13, 1 PCV10, 5 both), covering studies with various designs in six continents, using different schedules, were included. Collectively, they reported 469 VT IPD cases classified as vaccine failures and 403 as breakthrough. Vaccine failure and breakthrough rates were low: 8.4% and 9.3%, respectively, of all IPD in vaccinated children, consistent with the vaccines' high effectiveness. The main serotypes associated with vaccine failure/breakthrough were 19A, 3 and 19F for PCV13 and 14, 6B and vaccine-related 19A and 6A for PCV10.

EXPERT OPINION

As we move to vaccines with more serotypes, it is not only important to consider which serotypes are added, but also monitor and address incomplete protection against specific serotypes.

Authors+Show Affiliations

GSK, Yongsan-gu, Seoul, South Korea.GSK, Avenue Fleming 20, Wavre, Belgium.GSK, Oceanía Business Plaza (Torre 1000, Piso 34), Panama City, Panama.GSK, Avenue Fleming 20, Wavre, Belgium.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Systematic Review

Language

eng

PubMed ID

34882050

Citation

Mungall, Bruce A., et al. "A Systematic Review of Invasive Pneumococcal Disease Vaccine Failures and Breakthrough With Higher-valency Pneumococcal Conjugate Vaccines in Children." Expert Review of Vaccines, vol. 21, no. 2, 2022, pp. 201-214.
Mungall BA, Hoet B, Nieto Guevara J, et al. A systematic review of invasive pneumococcal disease vaccine failures and breakthrough with higher-valency pneumococcal conjugate vaccines in children. Expert Rev Vaccines. 2022;21(2):201-214.
Mungall, B. A., Hoet, B., Nieto Guevara, J., & Soumahoro, L. (2022). A systematic review of invasive pneumococcal disease vaccine failures and breakthrough with higher-valency pneumococcal conjugate vaccines in children. Expert Review of Vaccines, 21(2), 201-214. https://doi.org/10.1080/14760584.2022.2012455
Mungall BA, et al. A Systematic Review of Invasive Pneumococcal Disease Vaccine Failures and Breakthrough With Higher-valency Pneumococcal Conjugate Vaccines in Children. Expert Rev Vaccines. 2022;21(2):201-214. PubMed PMID: 34882050.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A systematic review of invasive pneumococcal disease vaccine failures and breakthrough with higher-valency pneumococcal conjugate vaccines in children. AU - Mungall,Bruce A, AU - Hoet,Bernard, AU - Nieto Guevara,Javier, AU - Soumahoro,Lamine, Y1 - 2022/02/03/ PY - 2021/12/10/pubmed PY - 2022/4/2/medline PY - 2021/12/9/entrez KW - Breakthrough disease KW - PCV10 KW - PCV13 KW - PHiD-CV KW - children KW - higher-valency KW - invasive pneumococcal disease KW - pneumococcal conjugate vaccine KW - vaccine failure SP - 201 EP - 214 JF - Expert review of vaccines JO - Expert Rev Vaccines VL - 21 IS - 2 N2 - INTRODUCTION: The pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccine (PHiD-CV/PCV10) and 13-valent pneumococcal conjugate vaccine (PCV13) protect against vaccine-serotype invasive pneumococcal disease (VT IPD). However, VT IPD can still occur in fully or partially vaccinated children (vaccine failure or breakthrough). We performed a systematic review of vaccine failures and breakthrough IPD with PCV10 and PCV13 in ≤5-year-olds. AREAS COVERED: We searched Scopus/Medline/EMBASE to retrieve articles/abstracts published between 1/2008-7/2019. We excluded reports only including data from ≥6-year-olds, exclusively assessing PCV7-vaccinated children or children with comorbidities. Twenty-six reports (20 PCV13, 1 PCV10, 5 both), covering studies with various designs in six continents, using different schedules, were included. Collectively, they reported 469 VT IPD cases classified as vaccine failures and 403 as breakthrough. Vaccine failure and breakthrough rates were low: 8.4% and 9.3%, respectively, of all IPD in vaccinated children, consistent with the vaccines' high effectiveness. The main serotypes associated with vaccine failure/breakthrough were 19A, 3 and 19F for PCV13 and 14, 6B and vaccine-related 19A and 6A for PCV10. EXPERT OPINION: As we move to vaccines with more serotypes, it is not only important to consider which serotypes are added, but also monitor and address incomplete protection against specific serotypes. SN - 1744-8395 UR - https://www.unboundmedicine.com/medline/citation/34882050/A_systematic_review_of_invasive_pneumococcal_disease_vaccine_failures_and_breakthrough_with_higher_valency_pneumococcal_conjugate_vaccines_in_children_ L2 - https://www.tandfonline.com/doi/full/10.1080/14760584.2022.2012455 DB - PRIME DP - Unbound Medicine ER -